Innovative Treatments for Blood Cancer and Inflammatory Eye Diseases
Senaste nytt
Our Projects
We develop innovative medicines for diseases with significant medical needs, such as blood cancer and inflammatory eye diseases. Our project portfolio includes both small, orally and topically active immunomodulatory molecules, as well as antibody-based immunotherapy.
Fully owned projects
Discovery
Preclinical
Phase I
Phase II
Phase III
Hematological malignancies
- Tasquinimod – Myelofibrosis
Partners:HOVONEurope
- Tasquinimod – Myelofibrosis
Partners:The University of TexasMD AndersonCancer CenterUSA
- Tasquinimod – Multiple Myeloma
Partners:Abramson Cancer CenterUSA
Inflammatory eye disorders
- Laquinimod – Eye Drops, Ocular Biodistribution
Partners:Stanford MedicineGorcUSA
Licensed projects
Discovery
Preclinical
Phase I
Phase II
Phase III
Solid tumors
- Naptumomab – Combination with anti-PDL1 (durvalumab) in solid tumors
Partners:NeoTXAstraZeneca
Financial Calendar
Interim Report Jan-Jun 2026
Interim Report Jan-Sep 2026
Year-end Report 2026
Share Information
- Ticker symbol: ACTI
- Marketplace: NASDAQ OMX Nordic Exchange (Stockholm)
- Listed since: 1986
- Shareholders: approximately 18,700
- Number of ordinary shares: 26,360,671
- Nominal value: 0.5164
About Us
Our goal is to develop new medicines for the improved treatment of diseases with significant medical needs. Our projects are based on extensive documentation and scientific expertise.
